Randomized double‐blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites

Passalacqua, Giovanni; Pasquali, M.; Ariano, R; Lombardi, Carlo; Giardini, Anna; Baiardini, Ilaria; Majani, Giuseppina; Falagiani, P.; Bruno, M.; Canonica, Giorgio Walter

doi:10.1111/j.1398-9995.2006.01095.x

Cited by 79 publications

(67 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86,87,108,109 Sublingual house dust mite (HDM) tablet immunotherapy for at least 1 year is recommended (Grade A) for the short-term treatment of perennial HDM AR in adults. [50][51][52][53][54][55] While higher doses and/or increased cumulative doses may be more effective, they may be associated with more side-effects [56][57][58] ; decisions on dose in AIT must be made balancing efficacy and sideeffects. 59 …”

Section: General Indications Key References Contextual Considerationsmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

594

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

Section: General Indications Key References Contextual Considerationsmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

594

705

View full text Add to dashboard Cite

show abstract

“…Wilson et al (1698) published a Cochrane Collaboration meta-analysis of SLIT in rhinitis and proposed that it was safe and effective. The Cochrane meta-analysis (1699) was followed by several studies which accorded with the results of the review (1103,(1700)(1701)(1702)(1703)(1704)(1705)(1706)(1707)(1708)(1709)(1710)(1711). Moreover, pivotal trials have been carried out and the results on over 600 patients showed convincingly that in grass pollen allergy, SLIT is safe and effective using tablets (1103,1712).…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

Self Cite

3,867

1,761

View full text Add to dashboard Cite

“…Finally, a sublingual allergoid tablet developed by Lofarma (Lais®) which contains HDM allergens modified by carbamylation is available in a number of countries on a named-patient product basis for the treatment of HDM allergic rhinitis [31,32]. This product is undergoing further clinical development in order to support a future marketing authorization application.…”

Section: Market Overviewmentioning

confidence: 99%

Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma

Canonica

Virchow

Zieglmayer

et al. 2016

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: In the treatment of house dust mite (HDM) respiratory allergic disease, allergy immunotherapy constitutes an add-on treatment option targeting the underlying immunological mechanisms of allergic disease. However, for the treatment of HDM allergic asthma, the use of subcutaneous allergy immunotherapy (SCIT) has been limited by the risk of systemic adverse events. Thus, sublingually administered allergy immunotherapy (SLIT) has been investigated as a treatment option with an improved tolerability profile that allows for safer treatment of patients with HDM allergic asthma. Areas covered: In this Drug Profile, we provide a review of the clinical data behind the SQ HDM SLITtablet, which was recently approved for the treatment of HDM allergic asthma and allergic rhinitis by regulatory authorities in several European countries. Expert commentary: The SQ HDM SLIT-tablet is the first allergy immunotherapy to be tested prospectively in patients with asthma, and to favorably modify patient relevant end points such as requirement for inhaled corticosteroid (ICS) or the time to first asthma exacerbation upon ICS reduction, suggesting that SQ HDM SLIT-tablet treatment may contribute to improving overall asthma control.

show abstract

Randomized double‐blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites

Abstract: Sublingual immunotherapy was clinically effective and safe in mite-induced mild disease.

Cited by 79 publications

References 27 publications

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma

Contact Info

Product

Resources

About